Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acarbose vs Glibenclamide on MAGE and Oxidative Stress in T2DM
NCT00417729Phase 4Completed
- Sponsor
- Taichung Veterans General Hospital
- Start
- Jan 2007
- Primary completion
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of acarbose in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Taichung Veterans General Hospital. Primary endpoints: Mean Amplitude of Glycemic Excursions at Week 16 and Urinary 8-iso Prostaglandin F2alpha at Week 16. Started Jan 2007; status: completed.
02
Drugs
acarbose
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00417729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00417729.